In its latest list of entities put under 'import alert', the US Food and Drug Administration (FDA) has named Mumbai-based Polydrug Laboratories' manufacturing plant in Ambernath Industrial Area.
The FDA has put this manufacturing plant under the import alert of 'Detention Without Physical Examination of drugs from firms which have not met drug good manufacturing practices'. Such a categorisation generally happens when the regulator's inspection has revealed that a firm is not operating in conformity with current good manufacturing practices.
In recent times, many Indian drug makers have come under the scanner of the FDA with regard to various quality issues.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
